Yajing Chen Sells 2,264 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 2,264 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $17.46, for a total transaction of $39,529.44. Following the sale, the chief financial officer owned 35,691 shares of the company’s stock, valued at $623,164.86. This represents a 5.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Yajing Chen also recently made the following trade(s):

• On Monday, April 6th, Yajing Chen sold 853 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total transaction of $17,443.85.
• On Thursday, April 2nd, Yajing Chen sold 5,199 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total value of $106,007.61.

Zai Lab Stock Performance

Shares of Zai Lab stock opened at $19.00 on Wednesday. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -11.73 and a beta of 0.78. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $15.96 and a fifty-two week high of $41.20. The stock has a 50 day moving average of $19.19 and a 200 day moving average of $18.96.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The business had revenue of $99.61 million for the quarter. Analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.23 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ZLAB shares. Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. JPMorgan Chase & Co. decreased their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Wall Street Zen lowered shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Citigroup dropped their price target on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.